Company Encyclopedia
View More
name
Altimmune
ALT.US
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
1.945 T
ALT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking224/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-52.61%E
    • Profit Margin-419575.00%E
    • Gross Margin-299100.00%E
  • Growth ScoreD
    • Revenue YoY-61.54%E
    • Net Profit YoY18.94%B
    • Total Assets YoY47.74%A
    • Net Assets YoY39.16%A
  • Cash ScoreD
    • Cash Flow Margin-0.02%D
    • OCF YoY-61.54%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio15.04%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Key facts: Altimmune appoints Jerry Durso as CEO; pemvidutide trial data pending

    Altimmune, Inc. will see Jerry Durso become CEO on January 1, 2026, succeeding Vipin Garg, who will remain an advisor until June 30, 2026.123Altimmune's pemvidutide targets liver disease and weight loss. Mid-stage trial data is due soon, and an FDA meeting for a late-stage study is set for this year.4

    TradingView·
    US
    ALT
    -1.00%
    TradingView·
    US
    ALT
    -1.00%

    BUZZ-Altimmune falls as CEO Vipin Garg to step down

    Shares of drug developer Altimmunefall 6.7% to $4.91 premarketCo says Chairman Jerry Durso will take over as chief executive officer on January 1, 2026, succeeding Vipin Garg, who has led the company for seven yearsCo says Durso previously led Intercept Pharmaceuticals and spent over 20 years at Sanofi (SASY.PA) Co’s lead drug pemvidutide is being developed for liver disease and weight loss - ALTALT expects 48-week mid-stage trial data and FDA meeting on proposed late-stage study before year-end, co saysUp to last close, stock down ~27% YTD

    Reuters·
    US
    ALT
    -1.00%
    Reuters·
    US
    ALT
    -1.00%

    Altimmune Announces CEO Transition, Succession Plan

    Altimmune Inc :ALTIMMUNE ANNOUNCES CEO TRANSITION AND SUCCESSION PLANALTIMMUNE INC - JERRY DURSO TO SUCCEED VIPIN GARG AS CEOALTIMMUNE INC - VIPIN GARG TO STEP DOWN AS CEO EFFECTIVE JAN 1, 2026ALTIMMUNE INC - JERRY DURSO TO ASSUME ROLE OF CEO AND RETAIN CHAIRMAN POSITIONALTIMMUNE INC - VIPIN GARG TO SERVE AS ADVISOR THROUGH JUNE 30, 2026

    Reuters·
    US
    ALT
    -1.00%
    Reuters·
    US
    ALT
    -1.00%

    Imdex to Acquire ALT and MSI to Boost Sensor and Digital Portfolio

    Imdex Limited is acquiring ALT and MSI to enhance its sensor and digital portfolio, expecting to add A$10 million in revenue and A$2 million in EBITDA by FY26. The acquisition, funded by cash and debt, will close in Q3 FY26, with potential deferred consideration up to €20 million. This move aims to broaden Imdex's offerings in earth systems markets.

    Reuters·
    US
    MSI
    +0.68%
    US
    ALT
    -1.00%
    Reuters·
    US
    MSI
    +0.68%
    US
    ALT
    -1.00%

    Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

    GAITHERSBURG, Md., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Altimmune, Inc. ( Nasdaq: ALT ) , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will ...

    GlobeNewswire·
    US
    ALT
    -1.00%
    GlobeNewswire·
    US
    ALT
    -1.00%
    © 2025 Longbridge｜Disclaimer